Risperidone for the core symptom domains of autism [10]

American Journal of Psychiatry

Volumn 163, Issue 3, 2006, Pages 551-

  Adetunji, Babatunde ^a   Mathews, Maju ^a   Osinowo, Thomas ^a   Williams, Adedapo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

AGGRESSION; AUTISM; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; FATIGUE; HUMAN; IRRITABILITY; LETTER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RATING SCALE; RITVO FREEMAN REAL LIFE RATING SCALE; SYMPTOM; METHODOLOGY; MULTICENTER STUDY; NOTE; PSYCHOLOGICAL ASPECT; STANDARD; STATISTICS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CLINICAL TRIALS; HUMANS; MULTICENTER STUDIES; PLACEBOS; RESEARCH DESIGN; RISPERIDONE; TREATMENT OUTCOME;

EID: 33645931984     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.163.3.551     Document Type: Letter

References (3)

1. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B: Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 2005; 162:1142-1148
2. Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314-321
3. Schreibman L: Intensive behavioral/psychoeducational treatments for autism: research needs and future directions. J Autism Dev Disord 2000; 30:373-378